Receive our newsletter – data, insights and analysis delivered to you
September 7, 2011

Aeris gets expanded EU approval for AeriSeal system

Aeris Therapeutics has received expanded CE Mark approval in Europe for the AeriSeal System used to treat patients with emphysema. The move follows the availability of new clinical data from a study in which patients received treatment in two regions in each lung during a single broncho

By cms admin

Aeris Therapeutics has received expanded CE Mark approval in Europe for the AeriSeal System used to treat patients with emphysema.

The move follows the availability of new clinical data from a study in which patients received treatment in two regions in each lung during a single bronchoscopic procedure.

The AeriSeal system uses a proprietary polymer sealant delivered through a bronchoscope to the damaged areas of the patient’s lungs to reduce lung volume without surgery.

Aeris Therapeutics CEO David Dove said that the approval meant that clinicians are able to treat more damaged lung regions in a single treatment session, which results in better outcomes from a single minimally invasive procedure.

”We can now accelerate our global commercialisation and scale up of clinical education and training programmes and make this therapy available to more patients suffering from emphysema,” Dove said.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
The powerful networks advancing life sciences in Charleston | USA
The power of infrastructure: How Charleston | SC | USA is expanding horizons for life science companies
Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Get important industry news and analysis sent to your inbox
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU